Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study

BACKGROUND & AIMS: Pretreatment predictors of finite nucleo(s)tide analogue (NUC) therapy remain elusive. We studied the association between pretreatment HBV DNA levels and outcomes after therapy cessation. METHODS: Patients with chronic hepatitis B who were HBeAg negative at the start of NUC tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonneveld, Milan J., Chiu, Shao-Ming, Park, Jun Yong, Brakenhoff, Sylvia M., Kaewdech, Apichat, Seto, Wai-Kay, Tanaka, Yasuhito, Carey, Ivana, Papatheodoridi, Margarita, Colombatto, Piero, van Bömmel, Florian, Berg, Thomas, Zoulim, Fabien, Ahn, Sang Hoon, Dalekos, George N., Erler, Nicole S., Brunetto, Maurizia, Wedemeyer, Heiner, Cornberg, Markus, Yuen, Man-Fung, Agarwal, Kosh, Boonstra, Andre, Buti, Maria, Piratvisuth, Teerha, Papatheodoridis, George, Chen, Chien-Hung, Maasoumy, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362794/
https://www.ncbi.nlm.nih.gov/pubmed/37484211
http://dx.doi.org/10.1016/j.jhepr.2023.100790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362794/
https://www.ncbi.nlm.nih.gov/pubmed/37484211
http://dx.doi.org/10.1016/j.jhepr.2023.100790

Ejemplares similares